+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Intragastric Balloon Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

  • ID: 5026023
  • Report
  • January 2022
  • Region: Global
  • 119 Pages
  • Mordor Intelligence


  • Apollo Endosurgery Inc.
  • Endalis
  • Hélioscopie
  • Lexel Medical
  • Obalon Therapeutics

The intragastric balloon market is expected to register a CAGR of 9% during the forecast period.

COVID-19 is likely to have a profound impact on the intragastric balloon market. People with an underlying condition such as obesity are at greater risk during the COVID-19 pandemic. As per the data published by the Center for Disease Control and Prevention in March 2021, around 30.2% of the total COVID-19 hospitalizations were attributed to obesity.

During the COVID-19 pandemic, obesity increased exponentially. As per an article published by the European Journal of Nutrition in December 2020, the rate of obesity increased in the world due to a change in lifestyle and a decrease in exercise practice among people, as they avoided gym and yoga classes due to the social distancing protocols. This increase in the obesity population is expected to drive the demand for intragastric balloons in the near future.

As per the data published by World Health Organization, in 2020, more than 1.9 billion adults, 18 years and older, were overweight. Among them, over 650 million were obese. Intragastric balloons are used in the treatment of obesity by placing the device temporarily in the stomach. They help people reduce weight by making them eat less. The high prevalence of obesity worldwide and the increasing adoption of weight-loss surgery, like sleeve gastrectomy and gastric bypass, are leading to high mortality due to obesity, which will surge the demand for alternative procedures and minimally invasive procedures such as intragastric balloons.

However, the side effects or complications associated with intragastric balloons may hamper the market growth.

Key Market Trends

The Single Intragastric Balloon Market is Estimated to Witness a Healthy Growth in the Future

Single intragastric balloons are estimated to witness healthy growth in the future, which is attributed to increasing awareness, rising demand for minimally invasive procedures, availability of many products in the market, and scientific proofs for their safety and efficacy. As per the National Institute of Health (NIH) report published in 2018, the Orbera intragastric balloon, a type of single fluid-filled intragastric balloon, is safe and effective for reducing obesity-related comorbidities in a real-world population and weight loss population.

The epidemic of obesity is impacting the severity of the COVID-19 pandemic. As per the data published by the Center of Disease Control and Prevention in 2021, obesity may triple the risk of hospitalization due to a COVID-19 infection, and it is linked to impaired immune function. Additionally, it decreases lung capacity and reserve and can make ventilation more difficult. Thus, benefits offered by the existing single balloon system, such as minimal downtime and fully reversible treatment, are anticipated to increase the demand for this type of intragastric balloon during the coming years.

Moreover, the increasing number of obese patients with several technological advancements for better outcomes and developments in the intragastric balloon will promote segment growth in the future. Factors, such as the rising intake of junk foods/fast foods, are resulting in declining health in the population worldwide, leading to an increase in the prevalence of obesity, especially in some developed parts of the world, which is likely to fuel vertical growth. For instance, in the United States, from 1999-2000 and 2017-2018, the prevalence of obesity increased from 30.5% to 42.4%, and the prevalence of severe obesity increased from 4.7% to 9.2%, as per the 2018 report by the Centers for Disease Control and Prevention. Obesity is expected to continue increasing over the forecast period, fueling the segment growth.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant market share in the global intragastric balloon market due to the increasing obese population and high adoption of weight loss treatments. As per the data provided by Organisation for Economic Co-operation and Development (OECD), in 2017, around 38.2% of the United State Population was obese, which is the highest in the World.

As per the data published by the Organization for Economic Co-operation and Development, in Canada, 59.1% of the population aged 15 years or more were obese, whereas, in Mexico, 75.2% of the population aged 15 years or more was obese in 2017- 2018.

Thus, there is high demand for minimally invasive procedures. The population in this region is more inclined to adopt new innovations, propelling the market growth in this region. Moreover, favorable regulatory scenarios, healthcare expenditure, and the presence of well-established healthcare infrastructure are fueling the growth of the overall regional market to a large extent.

As the pandemic impacted the business and quality of life of the population across the country, the treatments for most of them were postponed unless it was an emergency, negatively impacting the intragastric balloon market.

Competitive Landscape

The intragastric balloon market is moderately competitive with several major players. Some companies currently dominating the market are Obalon Therapeutics, Apollo Endosurgery Inc., Allurion Technologies Inc, Spatz3, ReShape Lifesciences, MEDSIL, Hélioscopie, and Silimed. Mergers and acquisitions, divestments, and new product developments and launches are the key strategies adopted by the established market players. A few emerging players are also involved in obtaining funding for their product developments and launches.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Apollo Endosurgery Inc.
  • Endalis
  • Hélioscopie
  • Lexel Medical
  • Obalon Therapeutics

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Adoption of Minimally Invasive Treatment
4.2.2 Increasing Prevalence of Obesity
4.3 Market Restraints
4.3.1 Side Effects or Complications Associated with Intragastric Balloons
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Type
5.1.1 Single
5.1.2 Dual
5.1.3 Triple
5.2 By Filling Material
5.2.1 Gas Filled
5.2.2 Saline Filled
5.3 By End User
5.3.1 Hospitals
5.3.2 Ambulatory Surgical Centers
5.3.3 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Rest of the World
6.1 Company Profiles
6.1.1 Obalon Therapeutics
6.1.2 Apollo Endosurgery Inc.
6.1.3 Allurion Technologies Inc.
6.1.4 Spatz3
6.1.5 ReShape Lifesciences
6.1.6 Lexel Medical
6.1.7 Endalis
6.1.8 MEDSIL
6.1.9 Hélioscopie
6.1.10 Silimed
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Obalon Therapeutics
  • Apollo Endosurgery Inc.
  • Allurion Technologies Inc.
  • Spatz3
  • ReShape Lifesciences
  • Lexel Medical
  • Endalis
  • Hélioscopie
  • Silimed
Note: Product cover images may vary from those shown